secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2022-07-14T23:59:59+00:00
Accession:  0001770787-22-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO
----------------------------------------------------------------------------

- Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.
- Americas rev grew 8% YoY to $70.9M; EMEA fell 11% to $25.6M; APAC fell 15% to $18.1M.
- CEO says results 'fell short of our expectations'; full Q2 results and FY2022 guidance on Aug 8.
- Appointed Jim Wilbur, Ph.D., as Chief Commercial Officer effective July 27; outgoing CCO Brad Crutchfield to transition through Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/0001770787-22-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/txg-20220712.htm
  HTML page:      https://secwatch.observer/filing/0001770787-22-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer